All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
EBMT 2018 | MAC versus RIC allo-HCT in patients with AML in CR2
Maria H. Gilleece, from Leeds Cancer Institute, Leeds, UK, presented at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), data from a retrospective study by the Acute Leukemia Working Party (ALWP) of the EBMT, which compared the impact of myeloablative (MAC) versus reduced intensity (RIC) conditioning on transplant outcomes in different age groups of a large cohort of acute myeloid leukemia (AML) patients in second complete remission (CR2).
In total, 1,879 AML patients in CR2 who received MAC (n = 1,010, median age at transplant = 42.8 years) or RIC (n = 869, median age at transplant = 57.3 years) between 2007–2016 were identified from the EBMT registry and analyzed in this retrospective study.
Key findings:
- Outcomes in all patients
- 2-year leukemia free survival (LFS): 52% (95% CI, 49.5–54.5)
- 2-year overall survival (OS): 58.7% (95% CI, 56.2–61.2)
- 2-year relapse incidence (RI): 28.9% (95% CI, 26.7–31.2)
- 2-year non relapse mortality: 19% (95% CI, 17.2–21)
- 2-year graft versus host disease (GvHD) relapse free survival (GRFS): 38.7% (95% CI: 36.2–41.1)
- 2-year chronic GvHD: 37.2%
- In patients aged ≥ 50 years, compared to MAC, RIC decreased NRM (HR = 0.535, P = 0.0004) with worse cGVHD (HR = 1.377, P = 0.03) but no impact on RI, LFS, GFRS or OS.
- RIC and MAC had similar outcomes in patients < 50 years
The speaker, Maria Gilleece, concluded by noting that “allo-HCT rescues more than 50% of AML patients achieving CR2 post-relapse”. Additionally, the findings of this retrospective study demonstrate that in AML patients in CR2, “RIC allo-HCT reduces procedural mortality in patients ≥ 50 years without increasing RI and provides equivalent outcomes to MAC allo-HCT in patients < 50 years”. She further added that the findings of this study should be confirmed in a prospective study.
References